Aparito - a wholly owned subsidiary of Eli Lilly and Company

Welcome to the team, Tatti. What job title should we give her? We're thinking Head of Pawsitivity... 🐶

📗New paper alert! 📗 In "Digital endpoints in clinical trials: emerging themes from a multi-stakeholder Knowledge Exchange event" the authors discuss how digital technologies can enable the decentralisation of #ClinicalTrials. 📚 Background Digital technologies, such as wearable devices and smartphone applications (apps), can enable the decentralisation of clinical trials by measuring endpoints in people’s chosen locations rather than in traditional clinical settings. Digital endpoints can allow high-frequency and sensitive measurements of health outcomes compared to visit-based endpoints which provide an episodic snapshot of a person’s health. However, there are underexplored challenges in this emerging space that require interdisciplinary and cross-sector collaboration. A multi-stakeholder Knowledge Exchange event was organised to facilitate conversations across silos within this research ecosystem. 👩🏽🔬Methods A survey was sent to an initial list of stakeholders to identify potential discussion topics. Additional stakeholders were identified through iterative discussions on perspectives that needed representation. Co-design meetings with attendees were held to discuss the scope, format and ethos of the event. The event itself featured a cross-disciplinary selection of talks, a panel discussion, small-group discussions facilitated via a rolling seating plan and audience participation via Slido. A transcript was generated from the day, which, together with the output from Slido, provided a record of the day’s discussions. Finally, meetings were held following the event to identify the key challenges for digital endpoints which emerged and reflections and recommendations for dissemination. 📊 Results Several challenges for digital endpoints were identified in the following areas: patient adherence and acceptability; algorithms and software for devices; design, analysis and conduct of clinical trials with digital endpoints; the environmental impact of digital endpoints; and the need for ongoing ethical support. Learnings taken for next generation events include the need to include additional stakeholder perspectives, such as those of funders and regulators, and the need for additional resources and facilitation to allow patient and public contributors to engage meaningfully during the event. Read the paper in full here 👇 https://hubs.li/Q02Kbg280

Thanks to Development Bank of Wales and all others that supported us along the way. Too many to list all here. It’s been an epic adventure over the last 10 years. I’m now looking forward to the new opportunities of digitising clinical trials and all things #eCOA as part of Eli Lilly and Company

Exciting news from Brussels this week as the #5G4PHealth project officially launches! 🎉 This groundbreaking project is set to revolutionize healthcare services by developing a 5G-powered platform that will connect P4-based healthcare services (predictive, preventive, personalized, participatory) across various specialties. Intending to improve profitability and efficiency in healthcare, the 5G4PHealth project brings together a diverse consortium of 16 entities, including tech and healthcare providers, researchers, academia, clinicians, and cybersecurity experts, from six European countries. We're excited to see the collaboration and innovation that will come from this project! 🏥

Merci beaucoup, Paris. 🇫🇷 We met with our #DT4RD partners where our first patient joined for lunch and made cake for us 🍰 #Patient engagement with the project has been encouraging with over 80% on #ePRO adherence and >60% of videos passing quality control!

The #UKFast50 represents the most dynamic players in all areas of #Tech. Could you be a 2024 winner?   Join the likes of Aparito - a wholly owned subsidiary of Eli Lilly and Company, Vizolution - a Lightico company and Laser Wire Solutions, Welsh businesses who've ranked in the Fast 50 in previous years, and raise your company's profile, gain industry recognition and showcase your business's achievements over the last four years.   To read more about this category find out more here: https://deloi.tt/4aYEGT4.   👉 Entries close Thursday 11th July, so don't delay! For full details visit: https://deloi.tt/2ZiSgvD.   #DeloittePrivate #technology #DeloitteWales

Aparito is now ISO/IEC 27001:2022 certified! 🥳 After congratulating our wonderful team, you may ask, what’s changed from ISO/IEC 27001:2013, and why does it matter? 🛡️With cybercrime on the rise and newer threats constantly emerging, managing cyber risks can seem difficult. ISO/IEC 27001:2022 helps us become risk-aware and proactively identify and address weaknesses, thereby strengthening our systems. 🔒 An information security management system implemented as per this standard is a tool for risk management, cyber-resilience, and operational excellence. ⚛️ ISO/IEC 27001:2022 promotes a holistic approach to information security: vetting people, policies, and technology. 🎛️ It increases senior leadership involvement in information security management, ensuring that information security and data integrity are front and centre in the strategic direction of Aparito and our #eCOA platform product roadmap. Atom5™ is built with integrated security and data quality. This certification further strengthens Atom5™ and aligns with Aparito’s founding principles of privacy by design.

Our latest webinar is now available on demand! 🦋 In "Facilitating Patient Preference in Rare Epilepsy Studies", we asked our panel of experts from epihunter SynGAP Research Fund (SRF) for SYNGAP1-Related Disorders and Fundación Síndrome de Dravet how we should capture data to balance the needs of regulators seeking real-world data and the #epilepsy patients and caregivers who want to measure what matters to them. View the recording here 👇 https://hubs.li/Q02C_8Cr0 #eCOA #DigitalHealth

On #XLHAwarenessDay, we revisit our publication, "A patient-centred and multi-stakeholder co-designed observational prospective study protocol: Example of the adolescent experience of treatment for X-linked hypophosphataemia (#XLH)", a diverse team of expert physicians, researchers, technology specialists, patients, and caregivers came together to co-design a prospective observational study on hashtag#XLH, a rare disease affecting adolescents. Collaboration and patient engagement were key in ensuring the study's success. The research team worked together to identify relevant research questions, select appropriate outcome measures, and assess the feasibility and acceptability of data collection methods. By involving patients, caregivers, and clinicians in the study design, the researchers ensured a patient-centric approach and gained valuable insights into the lived experience of the disease and its treatments. This patient-centric approach allowed for flexible research methods and a deep understanding of the disease, which is especially important for rare diseases where knowledge may be limited. Read the paper here 👇 https://hubs.li/Q02CQ0L30

Last call for today's webinar, Facilitating Patient Preference in Rare #Epilepsy Studies, which starts in <30 minutes! 💻 Register here ⬇️ https://hubs.li/Q02CNKs_0